| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 00:48 | Incyte wird auf der Jahrestagung 2026 der American Academy of Dermatology (AAD) die neuesten Daten aus der Hidradenitis suppurativa-Forschung vorstellen | 301 | Business Wire | Aktuelle, neu veröffentlichte 54-Wochen-Daten zur Behandlung von Hidradenitis suppurativa mit Pavorcitinib (STOP-HS1 STOP-HS2) werden im Mittelpunkt stehen
Die vorgestellten Abstracts über die Ruxolitinib-Creme... ► Artikel lesen | |
| Fr | KalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals to Present New EKTERLY (sebetralstat) Data at the 2026 Global Angioedema Leadership Conference | 213 | Business Wire | New interim data from the KONFIDENT-KID trial evaluating sebetralstat in children aged 2-11 accepted for late-breaking oral presentation KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced... ► Artikel lesen | |
| Fr | Biogen Inc.: Results from Real-World, Long-Term Treatment Persistence with LEQEMBI (lecanemab-irmb) in the United States Presented at AD/PD 2026 | 200 | GlobeNewswire (Europe) | TOKYO and CAMBRIDGE, Mass., March 20, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts... ► Artikel lesen | |
| Fr | Aquestive Therapeutics, Inc.: Aquestive Therapeutics Announces New Role of Lori J. Braender and Appointment of Thomas A. Zalewski as Chief Legal Officer and Chief Compliance Officer | 112 | GlobeNewswire (Europe) | Thomas A. Zalewski, a Partner at Day Pitney LLP, appointed Chief Legal Officer and Chief Compliance Officer effective April 2, 2026Lori J. Braender to remain in a non-executive role as Corporate Secretary... ► Artikel lesen |
| Unternehmen / Aktien | Kurs | Dividende 12M | Div.-Rendite | Erw. Dividende | Erw. Ex.-Datum | |
|---|---|---|---|---|---|---|
| AMGEN | 298,60 | 8,41 | +2,82 % | 2,52 | 15.05.2026 | |
| KAMADA | 8,490 | 0,22 | +2,59 % | 0,78 | 23.03.2026 | |
| ROYALTY PHARMA | 38,800 | 0,76 | +1,96 % | 0,24 | 20.02.2026 | |
| REGENERON PHARMACEUTICALS | 632,00 | 3,02 | +0,48 % | 0,94 | 20.02.2026 | |
| IONIS PHARMACEUTICALS | 61,04 | 0,00 | 0,00 % | |||
| BIOGEN | 157,75 | 0,00 | 0,00 % | |||
| VERA THERAPEUTICS | 40,650 | 0,00 | 0,00 % | |||
| LENZ THERAPEUTICS | 10,480 | 0,00 | 0,00 % |
| Aktien WKN | Akt. Kurs Vortag | +/- % | Zeit | ||
|---|---|---|---|---|---|
| 10X GENOMICS INC A2PPQJ Tradegate | 15,935 15,880 | +0,020 +0,13 % | 20.03. | ||
| 4D MOLECULAR THERAPEUTICS INC A2PS5P NASDAQ | 8,620 8,950 | -0,330 -3,69 % | 20.03. | ||
| AARDVARK THERAPEUTICS INC A412BL NASDAQ | 4,100 4,900 | -0,800 -16,33 % | 20.03. | ||
| ABCELLERA BIOLOGICS INC A2QKXS Tradegate | 3,030 3,063 | +0,059 +1,99 % | 20.03. | ||
| ABIVAX SA ADR A3EWCP Tradegate | 106,000 106,00 | +1,00 +0,95 % | 20.03. | ||
| ABSCI CORPORATION A3CVW3 NASDAQ | 2,970 3,075 | -0,105 -3,41 % | 20.03. | ||
| AC IMMUNE SA A2AR5F Tradegate | 2,490 2,680 | +0,010 +0,40 % | 20.03. | ||
| ACADIA PHARMACEUTICALS INC 603035 Stuttgart | 17,885 17,840 | 0,000 0,00 % | 20.03. | ||
| ACLARIS THERAPEUTICS INC A1412H Tradegate | 3,108 3,224 | -0,080 -2,51 % | 20.03. | ||
| ADAPTIVE BIOTECHNOLOGIES CORPORATION A2PLR5 Tradegate | 11,510 11,660 | -0,245 -2,08 % | 20.03. |